Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 03, 2017 07:30 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Announces Addition of Four Clinical Sites, Including Joslin Diabetes Center, for the Ongoing Phase 2 Study of CLBS03 in T1D

BASKING RIDGE, N.J., April 03, 2017 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company advancing a select therapeutic development...
March 17, 2017 07:00 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Announces 2016 Fourth Quarter and Full Year Financial Results

Annual revenue growth of 57% exceeds 2016 financial guidance Conference call begins today at 8:30 am Eastern time BASKING RIDGE, N.J., March 17, 2017 (GLOBE NEWSWIRE) -- Caladrius Biosciences,...
March 16, 2017 19:30 ET | Source: Caladrius Biosciences, Inc.

Hitachi Chemical Signs Agreement to Purchase from Caladrius Biosciences the Remaining 80.1% Interest in PCT for $75 Million

Caladrius expected to emerge as a well-capitalized cell therapeutics-only development company with multiple proprietary technology platforms Conference call begins tomorrow, March 17, 2017 at 8:30 am...
March 13, 2017 07:30 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences to Host 2016 Fourth Quarter and Full Year Financial Results Conference Call on March 17, 2017 at 8:30 am Eastern Time

BASKING RIDGE, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining a select therapeutic development...
March 02, 2017 07:30 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences to Present at Upcoming March Conferences

BASKING RIDGE, N.J., March 02, 2017 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining a select therapeutic development...
February 23, 2017 13:44 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Awarded $12.2 Million Grant from CIRM in Support of Phase 2 Clinical Trial of CLBS03 to Treat Type 1 Diabetes

BASKING RIDGE, N.J., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining a select therapeutic development...
February 01, 2017 07:30 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences to Present at Upcoming February Conferences

BASKING RIDGE, N.J., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining a select therapeutic development...
January 25, 2017 07:30 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Announces Addition of Three Clinical Sites, Including University of California, San Francisco, for the Ongoing Phase 2 Study of CLBS03 in T1D

BASKING RIDGE, N.J., Jan. 25, 2017 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining a select therapeutic development...
January 06, 2017 16:01 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Updates Status of Receipt of Funds for a Portion of Previously Announced Private Placement

BASKING RIDGE, N.J., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining a select therapeutic development...
January 03, 2017 07:30 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences to Present at Upcoming January Conferences

BASKING RIDGE, N.J., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining a select therapeutic development...